Co-development of urokinase-type plasminogen activator receptor-targeted radiological immunotherapy (RIT) Monopar Therapeutics Inc.(Wilmette, Illinois) and NorthStar Medical Radioisotopes, LLC (Beloit, Wisconsin) for the treatment of patients with severe COVID-19 Established a partnership with Aragen Bioscience, Inc. (Morgan Hill, California), a leading contract research organization that accelerates preclinical bioproduct development. Aragen will conduct research aimed at selecting the main candidate uPRIT to advance to the experimental new drug development stage for severe new coronary pneumonia.

"Aragen's expertise in preclinical research in this specific area will accelerate the selection of the main uPRIT based on the MNPR-101 antibody scaffold to advance to the clinical stage," said Dr. Andrew Mazar, Monopar's Chief Scientific Officer.

"We are very pleased to cooperate with Aragen at this important stage of the uPRIT program," said NorthStar Senior Vice President and Chief Scientific Officer Dr. James T. Harvey. "Using strict criteria to select uPRIT drug candidates to advance to experimental new drug research This is a key part of our new coronary pneumonia plan."

"UPRIT has great therapeutic potential for patients with severe new coronary pneumonia," said Axel Schleyer, Ph.D., CEO of Aragen. "We are delighted to be able to collaborate with Monopar and NorthStar on this important work."

The purpose of this collaboration is to identify uPRIT with the best urokinase-type plasminogen activator receptor binding, which can selectively transport cytotoxic radioisotopes to abnormally activated immune cells that produce "cytokine storm" It is these cells that have caused severe lung damage, multiple organ damage and death in patients with severe new coronary pneumonia.

About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of proprietary therapies that extend the life of cancer patients or improve their quality of life. Monopar's products at different stages of development include: Validive® for the prevention of severe oral mucositis caused by chemotherapy in patients with oropharyngeal cancer; camsirubicin for the treatment of advanced soft tissue sarcoma; and late-stage preclinical antibodies for advanced cancer and severe new coronary pneumonia MNPR-101. For more information, please visit: www.monopartx.com .

About NorthStar Medical Radioisotopes, LLC
NorthStar Medical Radioisotopes is a global innovative company that produces and distributes radioisotopes for medical imaging and therapeutic purposes. NorthStar is committed to providing reliable and environmentally friendly radioisotope supply solutions for the United States to meet patient needs and advance clinical research. The company's first product is the RadioGenix RadioGenix® system (technetium 99m generator); this is an innovative flexible platform technology that was first approved by the U.S. Food and Drug Administration in February 2018. For more information, please visit: www.northstarnm.com .

About Aragen Bioscience, Inc.
Aragen Bioscience, Inc. is a wholly-owned subsidiary of GVK BIO, headquartered in the San Francisco Bay Area, and is a leading contract research organization. Aragen Bioscience provides a variety of in vitro and in vivo services for the discovery, cell line development, production, characterization, viability and efficacy evaluation and development of biological and diagnostic products. For more information, please visit: www.aragenbio.com

Forward-looking statement
The statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" as described in the Private Securities Litigation Reform Act of 1995. "May", "will", "able", "will", "should", "anticipate", "plan", "anticipate", "intend", "believe", "estimate", "foretell", "Forecast," "potential," "continue," "target," and similar expressions are intended to indicate forward-looking statements, but not all forward-looking statements contain these identifiers. Examples of these forward-looking statements include statements about whether Aragen has the ability to select the main candidate uPRIT based on the MNPR-101 antibody scaffold, enter the development of experimental new drugs, and then enter the clinical stage of severe new coronary pneumonia; uPRIT for patients with severe new coronary pneumonia Whether it has great therapeutic potential; and whether the cooperation has the ability to identify uPRIT with the best urokinase-type plasminogen activator receptor binding, so that it can selectively transport cytotoxic radioisotopes to produce a "cytokine storm" "As a result, patients with severe new coronary pneumonia have severe lung damage, multiple organ damage and death abnormally activated immune cells. Examples of forward-looking statements include statements about the following: The risks and uncertainties involved in forward-looking statements include but are not limited to: lack of any clinical work on MNPR-101 so far; completion of preclinical and clinical development and commercialization The additional capital required for chemical potential; unable to combine MNPR-101 with therapeutic radioisotopes; the conjugate cannot kill abnormally activated and cytokine-producing immune cells; the conjugate cannot use uPAR to enter these cells and release a cytotoxic payload to kill These cells are killed and normal tissues are preserved at the same time; there is no guarantee that this radioisotope can be mass-produced and scaled up to meet potential demand; the level of demand cannot be determined once the treatment is available for commercial production; and about research, development, regulatory approval and treatment Various major comprehensive risks and uncertainties such as method commercialization. Actual results may differ materially from those expressed or implied in such forward-looking statements. In Monopar's filing with the Securities and Exchange Commission, a more comprehensive description of various risks is provided. All forward-looking statements contained in this press release only apply as of the date of the statement. Monopar, NorthStar, and Arabian are not obliged to update the above statement based on events or existing circumstances after the statement was issued. Any forward-looking statements contained in this press release represent only Monopar, NorthStar and Arag

Contact information:

Monopar Therapeutics Inc.:
Investor Relations:
Kim R. Tsuchimoto
Chief Financial Officer
kimtsu@monopartx.com

NorthStar Medical Radioisotopes, LLC:
Investor Relations:
Paul Estrem
Senior Vice President and Chief Financial Officer
pestrem@northstarnm.com

Aragen Bioscience, Inc.:
David Lustig
dlustig@aragenbio.com

 

Source: globenewswire.com

Report Abuse